Circulating glucagon-like peptide-1 (GLP-1) inhibits eating in male rats by acting in the hindbrain and without inducing avoidance
Keep the weight off SURMOUNT-4 evidence showed that stopping tirzepatide 15 mg led to substantial weight regain, while continuing it produced further loss (Aronne et al., JAMA 2024)
1,2 Although the clinical diagnosis of PD relies on the appearance of motor manifestations, extensive neuropathological dissemination initiates decades earlier, posing a significant challenge for early diagnosis
Due to the costly nature of GLP-1 RA therapy, the decision is made to discontinue treatment in non-responders
Method In this 7-day, randomized, single-blind, placebo-controlled, pilot study, 15 metabolic syndrome (MetS) patients (11/4 F/M
[23] However, the term MASLD accepts that there may be other conditions present, but focuses on the metabolic abnormalities contributing to the disorder